Nova Patents
EP3489680A3

Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors

Abstract

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

Term

4.8 yearsto projected expiry

Projected expiry 28 July 2031, counted from filing; an application has no term until it is granted.

  1. Priority and filed
  2. Published
  3. Today
  4. Projected expiry

Every citation, both ways

Citations
DocumentRelationOfficeCited during
WO2008112749A1CitesWorld Intellectual Property Organization (WIPO)Search report
US7932036B1CitesUnited States of AmericaSearch report
MITCH RAPONI ET AL: "A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia", BLOOD, vol. 111, no. 5, 1 August 2008 (2008-08-01), US, pages 2589 - 2596, XP055384548, ISSN: 0006-4971, DOI: 10.1182/blood-2007-09-112730Non-patent–Search report
DELPHINE ROLLAND ET AL: "Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial", CANCER CHEMOTHERAPY AND PHARMACOLOGY., vol. 65, no. 4, 4 December 2009 (2009-12-04), BERLIN., pages 781 - 790, XP055550806, ISSN: 0344-5704, DOI: 10.1007/s00280-009-1185-4Non-patent–Search report
U. BACHER ET AL: "Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies", BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 8, no. 3, 1 May 2009 (2009-05-01), pages 184 - 193, XP055106133, ISSN: 1473-9550, DOI: 10.1093/bfgp/elp011Non-patent–Search report
MITCH RAPONI ET AL: "RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML. | Blood Journal", BLOOD, 51ST ASH ANNUAL MEETING ABSTRACTS, vol. 114, no. 22, 20 November 2009 (2009-11-20), pages 4159, XP055550775Non-patent–Search report
G MARTINELLI ET AL: "Correlation of RASGRP1/APTX ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination.: Journal of Clinical Oncology: Vol 28, No 15_suppl", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15-suppl, 20 May 2010 (2010-05-20), pages 6550 - 6550, XP055551314, DOI: 10.1200/jco.2010.28.15_suppl.6550Non-patent–Search report
CRISTINA PAPAYANNIDIS ET AL: "Abstract #743: RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) | Cancer Research", 100TH AACR ANNUAL MEETING-- APR 18-22, 2009; DENVER, CO, vol. 69 issue 9 supplement, 1 May 2009 (2009-05-01), XP055551332Non-patent–Search report
J. E. KARP ET AL: "Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia", BLOOD, vol. 119, no. 1, 14 October 2011 (2011-10-14), pages 55 - 63, XP055103365, ISSN: 0006-4971, DOI: 10.1182/blood-2011-08-370825Non-patent–Search report